FDA grants AP status to Repaglinide ANDA207209 by Macleods Pharmaceuticals
The FDA has granted Abbreviated Approval (AP) status to ANDA207209 for Repaglinide submitted by Macleods Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Repaglinide with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.